Helios Technologies (HLIO) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 2025 net sales were $195.5M, down 8% year-over-year but up 9% sequentially, exceeding guidance and internal estimates; Hydraulics declined 11% and Electronics were nearly flat.
Adjusted EBITDA margin was 17.3%, with cash from operations up 7% year-over-year to $19.0M; net income was $7.3M, down 21% year-over-year.
Management is focused on customer-centric go-to-market initiatives, operational efficiency, and innovation, with ongoing restructuring and leadership transitions.
Early wins in new business, product launches, and positive order intake trends are supporting growth despite challenging markets.
Debt reduced for seven consecutive quarters, with net debt to adjusted EBITDA improved to 2.7x from 3.1x year-over-year.
Financial highlights
Net sales: $195.5M, down 8% year-over-year but $5M above high end of outlook; FX impact was -$2.3M.
Adjusted EBITDA margin: 17.3% (down 90 bps YoY); operating margin: 8.7%; adjusted operating margin: 13.4%.
Diluted EPS: $0.22, down 21% year-over-year; non-GAAP EPS: $0.44, down 17% year-over-year but up 33% sequentially.
Cash from operations: $19.0M, up 7% year-over-year; inventory reduced by 11%; capital expenditures: $6.1M (3% of sales).
Net debt to adjusted EBITDA at 2.7x; free cash flow conversion rate: 258% (trailing 12 months).
Outlook and guidance
Q2 2025 net sales expected at $198M–$206M, up 1–5% sequentially; adjusted EBITDA margin projected at 17.5–18.5%.
Non-GAAP EPS for Q2 expected at $0.46–$0.54, up 5–23% sequentially.
Full-year outlook not withdrawn, but guidance now focused on next quarter due to tariff and demand uncertainties.
Electronics segment sales expected to outpace Hydraulics; gross margin expected to expand sequentially.
Capital expenditures for 2025 forecasted at 3–4% of sales.
Latest events from Helios Technologies
- Raised FY2026 outlook after strong Q2 sales, margin gains, and record cash flow.HLIO
Q2 2026 - Strong 3Q25 growth and innovation drive a positive 2025 outlook, supported by a diversified portfolio.HLIO
Investor presentation - Imminent ARDS therapy launch in Japan and global phase III trial signal major growth ahead.HLIO
Jefferies Global Healthcare Conference 2026 - Q1 2026 sales up 17% with record margins, cash flow, and a raised full-year outlook.HLIO
Q1 2026 - Director elections, auditor ratification, and equity plan amendment up for shareholder vote.HLIO
Proxy filing - Growth, governance, and sustainability drive key proposals and leadership changes for 2026.HLIO
Proxy filing - Record Q4 and FY25 results, margin gains, and cash flow set up continued growth in FY26.HLIO
Q4 2025 - Sequential margin and cash flow gains offset year-over-year sales declines.HLIO
Q2 2024 - Transformation, margin expansion, and operational resilience drive future growth.HLIO
Baird 2024 Global Industrials Conference